首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

2046992

無針糖尿病護理市場－全球產業規模、佔有率、趨勢、機會、預測：按設備類型、最終用戶、地區和競爭對手分類，2021-2031年

Needle Free Diabetes Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type, By End User, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球無針糖尿病護理市場預計將從 2025 年的 142.9 億美元大幅成長至 2031 年的 202.6 億美元，複合年成長率為 5.99%。

此領域涵蓋光學感測、經皮吸收貼片和噴射注射器等醫療技術，無需使用侵入性針頭即可進行血糖值監測和胰島素注射。推動這一領域成長的關鍵因素包括全球糖尿病患者人數的不斷增加以及患者對無痛疼痛管理的強烈需求。這自然會提高治療依從性。此外，消除針刺傷風險和減少生物危害廢棄物也是促使醫療專業人員採用這些解決方案的原因。糖尿病在全球造成的沉重負擔凸顯了對這些創新解決方案的強勁需求。根據國際糖尿病聯盟 (IDF) 估計，到 2025 年，全球約有 5.89 億 20 至 79 歲的成年人患有糖尿病。儘管潛在用戶群體巨大，但市場擴張的主要障礙仍然是難以達到與傳統血液檢測相當的臨床準確性。這往往會導致監管核准延遲，並限制新產品的商業性可行性。

市場概覽
預測期	2027-2031
市場規模：2025年	142.9億美元
市場規模：2031年	202.6億美元
複合年成長率：2026-2031年	5.99%
成長最快的細分市場	胰島素幫浦
最大的市場	北美洲

市場促進因素

全球無針糖尿病護理市場的主要驅動力是全球糖尿病患者人數的不斷成長，這使得易於擴展、以患者為中心的管理工具的需求日益迫切。隨著糖尿病患者人數的增加，醫療保健系統面臨越來越大的壓力，因此需要能夠簡化日常監測和胰島素注射的設備，以提高患者的治療順從性。由於傳統的針刺療法常常會因不適和焦慮而阻礙患者的日常自我管理，因此，糖尿病患者人數的激增直接推動了對非侵入性治療方案的需求。國際糖尿病聯盟 (IDF) 的 2025 年預測強調了這一關鍵需求，預計到 2050 年，全球糖尿病成人患者人數將達到約 8.53 億。這凸顯了無針解決方案的巨大市場潛力，這些方案可以減輕治療負擔並改善患者的長期健康。同時，非侵入性胰島素注射和監測技術的快速發展正在重塑市場格局，有效地將臨床療效與使用者便利性結合。光學血糖感測器和噴射注射器等創新技術正從利基應用轉向現代醫學的核心組成部分，其重點在於減輕疼痛和實現數位整合。這種技術變革也體現在對特定細分市場的策略評估中。例如，NuGen Medical Devices在2025年8月發布的報告顯示，預計僅全球無針胰島素輸注市場規模就將達到150億美元。這些趨勢也受到醫療界觀點轉變的進一步推動，醫療界越來越重視技術解決方案。根據Dexcom在2025年6月進行的一項調查，59%的醫療專業人員認為，在未來十年，持續監測技術的普及將比藥物的進步對2型糖尿病的管理產生更大的影響。

市場挑戰

全球無針糖尿病照護市場面臨的主要障礙在於，如何證明其臨床準確性能夠與傳統血液檢測方法相提並論。監管機構對醫療設備有著嚴格的要求，要求非侵入性技術必須達到與有創血液採樣相同的準確性水平，以保障病人健康。目前許多創新技術難以在各種生理條件下維持穩定的準確性，導致核准流程漫長，並經常遭到監管機構的拒絕。這些延誤直接延緩了產品上市，阻礙了收入成長，並削弱了投資者對該領域短期潛力的信心。此外，缺乏檢驗的準確性也削弱了依賴準確數據進行胰島素給藥和患者照護等關鍵決策的醫護人員的信心。由於擔心測量結果的差異性可能會對患者預後產生負面影響，醫療服務提供者對將無針系統納入治療方案持謹慎態度。這種顧慮限制了該技術的應用範圍，使其僅限於健康管理領域，而非基礎醫療管理，從而嚴重阻礙了市場滲透。考慮到未確診患者群體，此一機會尤為重要。國際糖尿病聯盟（IDF）在2025年報告中估計，約有2.52億成年糖尿病患者不知情。市場能否有效拓展並服務於這個大規模且依賴診斷的群體，取決於能否持續確保臨床等級的準確性。

市場趨勢

將血糖值監測功能整合到消費級穿戴裝置中，從根本上改變了糖尿病管理的方式，將醫療級診斷功能融入日常生活用品中。領先的科技公司正超越基本的健身追蹤，透過將先進的光學感測器直接整合到智慧型手錶和戒指中，普及非侵入式監測。這一發展使得連續健康數據的收整合為可能，擺脫了專用醫療設備帶來的偏見和實際挑戰，從而實現更早的疾病檢測和更持續的用戶參與。為了體現這一戰略方向，《富比士》在2025年1月報道稱，三星計劃在其下一代Galaxy Watch手錶中加入非侵入式光學血糖監測功能，旨在規避與侵入式設備相關的傳統監管障礙。同時，可溶性微針貼片的興起正在革新藥物輸送物流，其耐熱、可自行給藥的解決方案無需低溫運輸儲存。與傳統的經皮吸收貼片不同，這些可生物分解的系統在使用後會完全溶解，避免了尖銳廢棄物的產生，並允許透過普通郵件遞送治療藥物。這項突破性進展將顯著降低偏遠和醫療資源匱乏地區患者獲得治療的障礙，從根本上改變胰島素和其他生物製藥的全球部署策略。 2025年1月，美光生物醫學公司宣布已獲得超過1,600萬美元的資金籌措，用於加速其可溶性微陣列技術在無針治療領域的商業性化生產，凸顯了該技術巨大的商業潛力。

The global market for needle-free diabetes care is projected to expand significantly, growing from USD 14.29 billion in 2025 to USD 20.26 billion by 2031, at a compound annual growth rate of 5.99%. This sector involves medical technologies like optical sensing, transdermal patches, and jet injectors that enable blood glucose monitoring or insulin delivery without invasive needles. Key factors fueling this growth include the rising global incidence of diabetes and a pronounced patient desire for pain-free management, which naturally enhances treatment adherence. Additionally, the adoption of these solutions by healthcare providers is incentivized by the elimination of needle-stick injury risks and a reduction in biohazard waste.The substantial global burden of diabetes underscores the robust demand for these innovative solutions; in 2025, an estimated 589 million adults aged 20 to 79 worldwide were living with diabetes, according to the International Diabetes Federation. Despite this large potential user base, a major obstacle to market expansion is the ongoing challenge of achieving clinical accuracy comparable to traditional blood-based methods. This often leads to delays in regulatory approvals and restricts the commercial viability of new products.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 14.29 Billion
Market Size 2031	USD 20.26 Billion
CAGR 2026-2031	5.99%
Fastest Growing Segment	Insulin Pumps
Largest Market	North America

Market Driver

The primary force propelling the Global Needle Free Diabetes Care Market is the increasing worldwide incidence of diabetes, which generates an urgent need for easily scalable and patient-centric management tools. As the number of individuals with diabetes grows, healthcare systems face mounting pressure, requiring devices that streamline daily monitoring and insulin administration to encourage consistent adherence. This demographic surge directly fuels demand for non-invasive options, given that traditional needle-based approaches often discourage regular self-management due to discomfort and apprehension. The International Diabetes Federation's 2025 projections highlight this critical demand, forecasting a global diabetic adult population of approximately 853 million by 2050, confirming a vast addressable market for needle-free solutions that can lessen treatment burdens and improve long-term health.Simultaneously, rapid advancements in non-invasive insulin delivery and monitoring technologies are reshaping the market by effectively combining clinical effectiveness with user convenience. Innovations like optical glucose sensing and jet injectors are transitioning from specialized uses to core components of contemporary care, emphasizing pain reduction and digital integration. This technological evolution is reflected in the strategic valuation of specific market segments; for instance, NuGen Medical Devices reported in August 2025 that the global needle-free insulin delivery market alone was estimated at a $15 billion opportunity. These developments are further supported by an evolving medical perspective that increasingly favors technological solutions; a June 2025 Dexcom survey showed that 59% of healthcare professionals believe improved access to continuous monitoring technology will be more impactful for Type 2 diabetes management over the next decade than advancements in medication.

Market Challenge

A significant obstacle for the Global Needle Free Diabetes Care Market is the challenge of proving clinical accuracy comparable to conventional blood-based testing methods. Regulatory agencies impose strict requirements for medical devices, demanding that non-invasive technologies meet the precision of invasive blood draws to safeguard patient well-being. Many current innovations struggle to achieve consistent accuracy across various physiological conditions, leading to lengthy approval processes and frequent rejections from regulators. These delays directly postpone product introductions, hinder revenue growth, and diminish investor confidence in the sector's short-term potential.Furthermore, the absence of verified precision undermines trust among healthcare professionals who rely on accurate data for critical decisions regarding insulin administration and patient care. Providers are hesitant to incorporate needle-free systems into treatment regimens, concerned that measurement inconsistencies could negatively impact patient outcomes. This reluctance limits the technology's application to wellness rather than essential medical management, thereby significantly restricting market penetration. The missed opportunity is considerable, especially considering the undiagnosed patient population; the International Diabetes Federation reported in 2025 that an estimated 252 million adults with diabetes were unaware of their condition. The market's ability to effectively expand and serve this large, diagnosis-reliant demographic hinges on the consistent assurance of clinical-grade accuracy.

Market Trends

The integration of consumer wearables with glucose sensing is profoundly transforming diabetes management accessibility by embedding medical-grade diagnostic capabilities into everyday lifestyle devices. Major technology companies are advancing beyond basic fitness tracking to incorporate sophisticated optical sensors directly into smartwatches and rings, thereby democratizing non-invasive monitoring. This evolution facilitates continuous health data collection, free from the stigma or logistical challenges associated with specialized medical hardware, which in turn promotes earlier disease detection and more consistent user engagement. Illustrating this strategic direction, Forbes reported in January 2025 that Samsung intends to include a non-invasive optical blood glucose monitoring feature in its upcoming Galaxy Watch models, with the goal of sidestepping conventional regulatory obstacles linked to invasive devices.Concurrently, the rise of dissolvable microneedle patch applications is innovating drug delivery logistics through the introduction of thermostable, self-administered solutions that eliminate the need for cold-chain storage. Unlike conventional transdermal patches, these biodegradable systems fully dissolve upon application, resulting in no sharps waste and enabling the distribution of therapeutics via standard mail. This breakthrough substantially reduces barriers for patients in remote or underserved areas, fundamentally changing global deployment strategies for insulin and other biologics. Micron Biomedical's announcement in January 2025, securing over $16 million in funding to expedite the commercial manufacturing of its dissolvable microarray technology for needle-free therapeutics, validates the significant commercial potential of this technology.

Key Market Players

3M Company
Bioject Medical Technologies Inc
Valeritas Inc
Antares Pharma Inc
Endo International PLC
InsuJet
Pharmajet Inc
INJEX Pharma AG
Johnson & Johnson
MannKind Corporation

Report Scope

In this report, the Global Needle Free Diabetes Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Needle Free Diabetes Care Market, By Device Type

Insulin Infuser
Insulin Patches
Insulin Pens
Insulin Pumps
Jet Injectors

Needle Free Diabetes Care Market, By End User

Homecare
Diagnostic Center
Hospitals & Clinic

Needle Free Diabetes Care Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Needle Free Diabetes Care Market.

Available Customizations:

Global Needle Free Diabetes Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Needle Free Diabetes Care Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 5.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Needle Free Diabetes Care Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Device Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Needle Free Diabetes Care Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Device Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Needle Free Diabetes Care Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Device Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Needle Free Diabetes Care Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Device Type
    - 6.3.3.2.2. By End User

7. Europe Needle Free Diabetes Care Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Device Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Needle Free Diabetes Care Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Device Type
    - 7.3.1.2.2. By End User
- 7.3.2. France Needle Free Diabetes Care Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Device Type
    - 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Needle Free Diabetes Care Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Device Type
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Needle Free Diabetes Care Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Device Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Needle Free Diabetes Care Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Device Type
    - 7.3.5.2.2. By End User

8. Asia Pacific Needle Free Diabetes Care Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Device Type
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Needle Free Diabetes Care Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Device Type
    - 8.3.1.2.2. By End User
- 8.3.2. India Needle Free Diabetes Care Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Device Type
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Needle Free Diabetes Care Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Device Type
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Needle Free Diabetes Care Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Device Type
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Needle Free Diabetes Care Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Device Type
    - 8.3.5.2.2. By End User

9. Middle East & Africa Needle Free Diabetes Care Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Device Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Needle Free Diabetes Care Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Device Type
    - 9.3.1.2.2. By End User
- 9.3.2. UAE Needle Free Diabetes Care Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Device Type
    - 9.3.2.2.2. By End User
- 9.3.3. South Africa Needle Free Diabetes Care Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Device Type
    - 9.3.3.2.2. By End User

10. South America Needle Free Diabetes Care Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Device Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Needle Free Diabetes Care Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Device Type
    - 10.3.1.2.2. By End User
- 10.3.2. Colombia Needle Free Diabetes Care Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Device Type
    - 10.3.2.2.2. By End User
- 10.3.3. Argentina Needle Free Diabetes Care Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Device Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Needle Free Diabetes Care Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. 3M Company
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Bioject Medical Technologies Inc
15.3. Valeritas Inc
15.4. Antares Pharma Inc
15.5. Endo International PLC
15.6. InsuJet
15.7. Pharmajet Inc
15.8. INJEX Pharma AG
15.9. Johnson & Johnson
15.10. MannKind Corporation